Oral miltefosine to treat new world cutaneous leishmaniasis

Lancet Infectious Diseases

Volumn 7, Issue 1, 2007, Pages 7-

  Soto, Jaime ^a   Toledo, Julia T ^b  

^a Fundacion Fader   (Colombia)

^b Centro de Investigaciones Bioclínicas   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; ANTIMONY; CREATININE; LIVER ENZYME; MEGLUMINE ANTIMONATE; MILTEFOSINE; PANCREAS ENZYME;

ARTHRALGIA; BOLIVIA; CLINICAL FEATURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE PAIN; LEISHMANIA BRAZILIENSIS; LETTER; MYALGIA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; PHOSPHORYLCHOLINE;

EID: 33845488153     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70665-X     Document Type: Letter

References (3)

1. Schwartz E., Hatz C., and Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 6 (2006) 342-349
2. Soto J., Arana B., Toledo J., et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 (2004) 1266-1272
3. Soto J, Toledo J, Balderrama M, et al, et al: Experience with Impavido (INN: Miltefosine) in Leishmania braziliensis infections. Northern European Conference on Travel Medicine; Edinburgh, UK; June 7-10, 2006.